1. Home
  2. IDYA vs EXPI Comparison

IDYA vs EXPI Comparison

Compare IDYA & EXPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • EXPI
  • Stock Information
  • Founded
  • IDYA 2015
  • EXPI 2008
  • Country
  • IDYA United States
  • EXPI United States
  • Employees
  • IDYA N/A
  • EXPI N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • EXPI Real Estate
  • Sector
  • IDYA Health Care
  • EXPI Finance
  • Exchange
  • IDYA Nasdaq
  • EXPI Nasdaq
  • Market Cap
  • IDYA 1.5B
  • EXPI 1.3B
  • IPO Year
  • IDYA 2019
  • EXPI N/A
  • Fundamental
  • Price
  • IDYA $21.22
  • EXPI $8.34
  • Analyst Decision
  • IDYA Strong Buy
  • EXPI Buy
  • Analyst Count
  • IDYA 12
  • EXPI 2
  • Target Price
  • IDYA $54.27
  • EXPI $10.75
  • AVG Volume (30 Days)
  • IDYA 1.5M
  • EXPI 1.4M
  • Earning Date
  • IDYA 05-06-2025
  • EXPI 05-06-2025
  • Dividend Yield
  • IDYA N/A
  • EXPI 2.40%
  • EPS Growth
  • IDYA N/A
  • EXPI N/A
  • EPS
  • IDYA N/A
  • EXPI N/A
  • Revenue
  • IDYA $7,000,000.00
  • EXPI $4,579,524,000.00
  • Revenue This Year
  • IDYA $68.39
  • EXPI $4.98
  • Revenue Next Year
  • IDYA $324.54
  • EXPI $9.47
  • P/E Ratio
  • IDYA N/A
  • EXPI N/A
  • Revenue Growth
  • IDYA N/A
  • EXPI 4.83
  • 52 Week Low
  • IDYA $13.45
  • EXPI $6.90
  • 52 Week High
  • IDYA $44.42
  • EXPI $15.39
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 65.40
  • EXPI 51.09
  • Support Level
  • IDYA $19.26
  • EXPI $7.48
  • Resistance Level
  • IDYA $20.46
  • EXPI $9.32
  • Average True Range (ATR)
  • IDYA 1.01
  • EXPI 0.30
  • MACD
  • IDYA 0.24
  • EXPI 0.12
  • Stochastic Oscillator
  • IDYA 99.55
  • EXPI 46.88

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About EXPI eXp World Holdings Inc.

eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services. The company mainly operates in the United States and Canada, and it also has operations in the United Kingdom, Australia, South Africa, France, India, Portugal, and Mexico, among others.

Share on Social Networks: